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Abstract
Background: Neuroinflammation is associated with virtually all major neurodegenerative disorders, including Alzheimer’s
disease (AD). Although it remains unclear whether neuroinflammation is the driving force behind these disorders,
compelling evidence implicates its role in exacerbating disease progression, with a key player being the potent
proinflammatory cytokine TNF-α. Elevated TNF-α levels are commonly detected in the clinic and animal models of AD.
Methods: The potential benefits of a novel TNF-α-lowering agent, 3,6′-dithiothalidomide, were investigated in cellular and
rodent models of neuroinflammation with a specific focus on AD. These included central and systemic inflammation
induced by lipopolysaccharide (LPS) and Aβ1–42 challenge, and biochemical and behavioral assessment of 3xTg-AD mice
following chronic 3,6′-dithiothaliodmide.
Results: 3,6′-Dithiothaliodmide lowered TNF-α, nitrite (an indicator of oxidative damage) and secreted amyloid precursor
protein (sAPP) levels in LPS-activated macrophage-like cells (RAW 264.7 cells). This translated into reduced central and
systemic TNF-α production in acute LPS-challenged rats, and to a reduction of neuroinflammatory markers and
restoration of neuronal plasticity following chronic central challenge of LPS. In mice centrally challenged with Aβ1–42
peptide, prior systemic 3,6′-dithiothalidomide suppressed Aβ-induced memory dysfunction, microglial activation and
neuronal degeneration. Chronic 3,6′-dithiothalidomide administration to an elderly symptomatic cohort of 3xTg-AD mice
reduced multiple hallmark features of AD, including phosphorylated tau protein, APP, Aβ peptide and Aβ-plaque number
along with deficits in memory function to levels present in younger adult cognitively unimpaired 3xTg-AD mice. Levels of
the synaptic proteins, SNAP25 and synaptophysin, were found to be elevated in older symptomatic drug-treated 3xTg-AD
mice compared to vehicle-treated ones, indicative of a preservation of synaptic function during drug treatment.
Conclusions: Our data suggest a strong beneficial effect of 3,6′-dithiothalidomide in the setting of neuroinflammation
and AD, supporting a role for neuroinflammation and TNF-α in disease progression and their targeting as a means of
clinical management.
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Background
Neuroinflammation is a critical and invariable compo-
nent of many neurodegenerative diseases. Indeed, the
co-occurrence of inflammatory markers in plasma, cere-
bral spinal fluid (CSF) and post-mortem brain tissue has
become a hallmark feature of Alzheimer’s disease (AD)
and Parkinson’s disease (PD) [1-4]. This has given rise to
the suggestion that inflammation within the CNS is an
important contributing factor in the continuum of neu-
rodegeneration, particularly in AD. The cytokine tumor
necrosis factor-alpha (TNF-α) is a major mediator of in-
flammation that is commonly upregulated in biological
samples from patients and animal models of human
neurodegenerative disease [5-12]. In brain, TNF-α is pri-
marily synthesized and released by glial cells that can be
activated by trauma, infection or the presence of en-
dogenous yet abnormal protein aggregates, such as
amyloid-β (Aβ) peptides in AD. Furthermore, cytokines,
including TNF-α, have been demonstrated to self-
regulate immune/glial cells to increase their expression
of amyloid-β precursor protein and Aβ in vitro [13].
Thus, in addition to the synthesis and release of cyto-
toxic factors, glial cells possess the ability, under appro-
priate conditions, to be an important non-neuronal,
source of abnormal APP in brain, a hallmark feature in
AD [14,15]. The existence of an altered brain micro-
environment observed in neurodegenerative disease
allows for and increases the likelihood of the generation
of an unregulated immune response that potentiates any
ongoing toxicity toward neurons.
In human post-mortem AD brain, a dramatic loss in
neurons has been observed in the medial temporal lobe
(hippocampus and entorhinal cortex). Over time, AD
patients develop classical patterns of brain pathology, as
described by Braak and Braak [16], and corresponding
cognitive impairments [14]. Early stages of dementia
may be associated with neuronal dysfunction causing the
observed cognitive impairments rather than overt cell
loss. It is possible that neuronal dysfunction is related to
the presence of inflammatory factors, as rodent models
of chronic neuroinflammation have been shown to in-
duce impaired states of learning and memory in vivo
[17,18]. In line with this, the expressions of genes asso-
ciated with learning and memory have been reported to
be altered by LPS administration in mice [19]. Addition-
ally, disturbances in biochemical and functional corre-
lates of learning at the cellular level, such as long-term
potentiation (LTP) [20] and neural network activity [21],
have been observed in models that mimic AD pathology.
These findings support the concept that inflammation
exacerbates the existing processes of neurodegeneration
observed in AD.
It is plausible that the dysfunction of viable neurons dur-
ing early stages of AD may not represent a permanent state
and may thus be amenable to rescue, potentially providing
improved outcomes for long-term nerve cell survival and
function. Transgenic animal models are commonly used to
investigate pathological processes of neurodegenerative dis-
eases; one such model is the 3xTg-AD mouse model [22].
Data from 3xTg-AD mice suggest a clear involvement of
cytokines, particularly TNF-α at pre-symptomatic stages of
AD pathology [23]. Additionally, the use of this model has
shown that in some circumstances neurons express TNF-α
gene products [24], and that reduced TNF-α signaling [25]
and microglia activation [26] mitigated disease progression.
Herein, to further define the role of TNF-α in neuroin-
flammation, neuronal dysfunction and cognitive impair-
ment, we utilized a TNF-α synthesis-lowering agent,
3,6′-dithiothalidomide, developed within our laboratory
[27]. This agent has been shown to effectively lower the
levels of TNF-α and nitrite, a surrogate of nitric oxide
metabolism, in LPS-treated macrophage-like cells
in vitro [28], to reverse established hippocampus-
dependent cognitive deficits induced by chronic neu-
roinflammation [29], as well as to reverse learning and
memory behavioral deficits in a rodent model of head
trauma [30]. We therefore assessed the biochemical and
behavioral actions of 3,6′-dithiothalidomide in three
models of neuroinflammation and in 3xTg-AD mice to
evaluate TNF-α as a neurological drug target in AD.
Methods and materials
Pharmacological interventions
3,6′-Dithiothalidomide was prepared in 100% tissue cul-
ture grade dimethyl sulfoxide (DMSO, Sigma-Aldrich, St
Louis, MO) for cell culture experiments, or as a suspen-
sion in a 1% carboxy methyl cellulose/saline solution
(Fluka 21901). A concentration of 56 mg/kg body weight
of drug was used for animal work unless stated other-
wise. Lipopolysaccharide (LPS) was obtained from
Escherichia coli (E coli) serotype 055:B5 (Sigma-Aldrich).
Aβ1–42 or Aβ42–1 peptides were from American Peptide,
Sunnyvale, CA.
Cell culture
Mouse RAW 264.7 cells were purchased from ATCC
(Manassas, VA, USA) and were grown in DMEM media
supplemented with 10% FCS, penicillin 100 U/ml and
streptomycin 100 μg/ml, and were maintained at 37°C
and 5% CO2. Cells were propagated as described by
ATCC guidelines. RAW 264.7 cells were cultured as has
been previously described [28,31]. Cells were challenged
with concentrations of LPS as indicated, and 24 h later,
conditioned media was harvested and analyzed for the
quantification of secreted TNF-α protein, nitrite and
APP levels. Cellular health was assessed by use of the
CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI).
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Acute animal LPS drug study
An in vivo assessment of the effects of 3,6′-dithiothali-
domide on the biosynthesis of LPS-induced TNF-α
mRNA and protein was undertaken. The levels of hippo-
campal mRNA, plasma and CNS protein were deter-
mined. Male Fisher 344 rats (3 months of age) were
challenged with LPS (1 mg/kg body weight, via the i.p.
route). A series of blood samples were taken from the
rats over a 5-h time period: [−60, 0 (LPS challenge), 30,
60, 90, 120, 180 and 240 min post LPS], plasma was gen-
erated from blood by conventional means. After
240 min the CNS was harvested, and all samples were
immediately frozen to −70°C and stored for analyses.
Chronic intracerebroventricularly animal LPS drug study
The rodents used for these experiments where male Fisher
344 rats (3 months of age). Four study groups were utilized:
(1) artificial cerebrospinal fluid (aCSF) plus drug vehicle
(aCSF-veh; n=4); (2) aCSF plus 3,6′-dithiothalidomide
(aCSF-DT; n=6); (3) LPS plus drug vehicle (LPS-veh; n=5)
and (4) LPS plus 3,6′-dithiothalidomide (LPS-DT; n=7).
The LPS or aCSF were infused directly into the brain via an
intracerebroventricular (i.c.v.) catheter (placement coordi-
nates: 2.5 mm posterior to lambda, on the mid-line and
7.0 mm ventral to the dura) into the lateral ventricle as pre-
viously described [17,18,21,29]. Animals received daily i.p.
administration of 3,6′-dithiothalidomide (56 mg/kg) or ve-
hicle for 14 days starting the day of the surgery. On day 14
after surgery, each animal was placed in an open field and
allowed to explore for 10 min. The open field environment
consisted of a circular chamber (130 cm in diameter, 25 cm
high) containing four different objects in the center. Total
distance moved and time spent in different zones of the
chamber were recorded with EthoVison XT software from
Noldus (Noldus, Nijmegen Area, The Netherlands). All ani-
mals were euthanized by anesthesia in an isoflurane cham-
ber followed by decapitation immediately after exploration.
To ensure that transcription induced by euthanasia would
not be detectable, the brain was quickly removed (between
120–150 s) and flash frozen in −80°C ice cold isopentane
[17,18,21,29]. The fresh frozen brains were stored at −70°C
until processing for in situ hybridization and fluorescence
immunostaining as previously described [17,18,21,29].
Acute intracerebroventricular Aβ1–42 peptide animal drug
study
Adult male C57BL/6 mice (3 months of age) were uti-
lized in this study. Mice received 3,6′-dithiothalidomide
(56 mg/kg, i.p.) or vehicle daily for 14 days; after 7 days
of treatment with drug animals were challenged with Aβ
peptide. Aβ1–42 and the reverse peptide Aβ42–1 were
reconstituted in phosphate-buffered saline (pH 7.4) and
aggregated by incubation at 37°C for 7 days prior to ad-
ministration. Aβ1–42 and Aβ42–1 (400 pmol) were then
infused i.c.v. into the lateral ventricle as previously
described [32].
3xTg-AD animal drug study
Adult and old male 3xTg-AD mice (10 and 17 months
of age) were maintained on a 12-h light/dark cycle with
free access to water and food. Animals received adminis-
tration of either 3,6′-dithiothalidomide (42 mg/kg) or
the vehicle i.p., daily for 6 weeks. Four to five weeks after
the initiation of drug treatment, the animals were tested
in the Morris Water Maze to assess acquisition (learn-
ing) and retention of spatial memory. After the comple-
tion of the Morris Water Maze assessment, the animals
were euthanized by decapitation while under isoflurane
anesthesia. The brain was immediately removed, and
specific regions were excised and instantly frozen to
allow later quantification of levels of various cortical
proteins of interest: soluble Aβ1–42, total tissue APP, tau
and phospho-tau protein, and the presynaptic proteins:
SNAP25 and synaptophysin.
All animal studies were undertaken according to pro-
tocols approved by the respective Institutional Animal
Care and Use Committee’s of the Intramural Research
Program, National Institute on Aging (331-LNS-2012,
293-LNS-2013 and NICHD # 08–011), and the Univer-
sity of California (AN082537-03A), in compliance with
the guidelines for animal experimentation of the Na-
tional Institutes of Health (Department of Health, Edu-
cation, and Welfare publication 85–23, revised, 1995).
Quantitative RT-PCR for rat TNF-α mRNA
Total mRNA was isolated from the hippocampus using
the RNeasy RNA isolation kit (Qiagen, Valencia, CA).
Various concentrations of total mRNA extracted from
rat brain were prepared for the generation of absolute
and relative standard curves. The RNA samples and ser-
ial dilutions for standard curves were reverse-transcribed
(Applied Biosystems), and PCR reactions were carried
out using primers and probe sets purchased from Ap-
plied Biosystems (Foster City, CA): the TNF-α primers
and probe set recognize exon 2–3 of TNF-α (assay loca-
tion 391, GenBank accession NM_012675.2), and the
GAPDH primers and probe set recognize exon 3 (assay
location 295, GenBank accession NM_017008.3). The
signals from the amplified PCR products were detected
using the ABI Prism 7700 Sequence Detection System
(Applied Biosystems), and obtained Ct values were cal-
culated to the relative amount of RNA from the stand-
ard curves for each RNA transcript.
ELISA analysis
TNF-α levels were measured by species-specific ELISAs;
Mouse RAW 264.7 cell culture media TNF-α protein
were measured with a mouse ELISA, BioLegend, Mouse
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TNF-α ELISA MAX™ Deluxe. Rat plasma and CNS pro-
tein was measured with a rat ELISA, BD OptEIA Rat
TNF ELISA Kit II, BD Biosciences or an Ultrasensitive
rat TNF-α, Invitrogen, respectively. Soluble human Aβ1–
42, levels were measured by use of a human Aβ42 ELISA
kit from Invitrogen. For all ELISA measurements, sam-
ples were assayed in duplicate, and the appropriate pro-
cedures were followed according to the manufacturer’s
instructions.
Immunohistochemistry
The brains of animals that received i.c.v. administered
LPS or Aβ peptides were processed as previously
described for the appropriate procedure [17,18,21,29,32].
For rat i.c.v. LPS studies, tissue was labeled with the fol-
lowing primary antibodies: MHC class II marker OX-6
(Pharmigen, San Diego, CA) for activated microglia and
glial fibrillary acidic protein (GFAP; Pharmigen) for acti-
vated astrocytes; nuclei were counterstained with Sytox-
Green (molecular Probes, Eugene, OR). Arc mRNA de-
tection was performed as previously described
[17,18,21]. Activated microglia numbers were quantified
in the DG and CA3 area as previously described [18,29].
For mouse i.c.v. Aβ peptide studies activated microglia
were identified and labeled with rabbit anti-CD11b
(1:200; Chemicon, Temecula, CA). Fuoro-Jade B, a
fluorochrome, was used to aid in the quantification of
degenerating neurons in the dentate gyrus [33,34]. For
mouse 3xTg-AD studies activated microglial cells in the
subiculum and CA1 region were visualized using an
anti-CD68 (Serotec) primary antibody.
Morris water maze test
Spatial learning and memory were assessed using the
Morris Water Maze. The target platform was submerged
1 cm below the water surface and placed at the midpoint
of one quadrant. Visual cues were placed around the
tank to orient the mice. The acquisition training sessions
took place over 4 days (for i.c.v. Aβ peptide-injected
mice, 3 days after Aβ administration) or over 6 days (for
3xTg-AD mice, 4 to 5 weeks after initiation of drug
treatment). The memory retention assessments were
performed at 24 h (Aβ peptide-injected mice) or at 4
and 24 h (3xTg-AD mice) after the last training session.
The variables of interest were mouse reference memory,
the time spent in the platform area and the number of
platform crossings. These events were recorded and ana-
lyzed to determine age- and drug-related differences be-
tween the groups.
Western blotting
Secreted APP levels were measured by Western blotting of
equal volumes of harvested culture media after separation
in a 10% Bis-Tris protein gel and probed with an antibody
that recognizes all forms of APP (22 C11; Millipore, Biller-
ica, MA). For 3xTg-AD mouse studies protein from each
sample was separated by electrophoresis in Criterion gels
(BioRad), then the transferred proteins were probed for
APP (clone 6E10, Covance, Emeryville, CA), phospho and
non-phospho tau (Thermo Scientific, Rockford, IL); SNAP
25 (Millipore), and synaptophysin (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Protein signals were obtained by
chemiluminescence substrate methods, and signals were
normalized to β-actin (GE/Amersham) [35,36].
Statistical analysis
GraphPad Prism software was used to perform the stat-
istical analysis of the following variables: plasma and
CNS TNF-α levels; hippocampus TNF-α mRNA; Morris
Water Maze platform escape latency; time spent in
quadrants and platform crossings. A one-way ANOVA
was performed on each group followed by a Bonferroni’s
post test or a Fisher’s post-hoc test, where appropriate.
For two-group comparisons, unpaired Student’s t-tests
were carried out. One-way ANOVA was performed for
variables measured from RAW 264.7 cells, TNF-α, ni-
trite and sAPP, and were followed by Bonferroni’s post
hoc tests, where appropriate. For the immunostaining
analysis, the control and experimental groups were the
independent variable, and the percentages of neurons
expressing Arc or activated microglia from various cat-
egories were the dependent variables. When an ANOVA
was significant (p< 0.001), individual between-group
comparisons were performed with Bonferroni’s post hoc
tests to correct for multiple comparisons. Statistical ana-
lyses are provided in each figure legend and, where ap-
propriate, involved one- or two-tailed t-tests for specific
comparisons.
Results
3,6′-Dithiothalidomide attenuates the synthesis of
inflammatory mediators in vitro and in vivo
The lipophilic, small molecular weight (mw: 290), TNF-α
synthesis-lowering agent 3,6′-dithiothalidomide [27] was
utilized in a series of studies aimed at assessing the role of
TNF-α on neuroinflammation directed at an AD-like
phenotype. RAW 264.7 cells treated with LPS recapitulate
aspects of microglial cells observed in neurodegenerative
diseases exemplified by AD. A challenge of RAW 264.7
cells with increasing concentrations of LPS induced a dose-
dependent generation of TNF-α protein (Figure 1A), nitrite
an intermediate of nitric oxide metabolism (Figure 1A) and
the secretion of amyloid precursor protein (sAPP) into cul-
ture media, suggestive of an upregulated processing of APP
(Figure 1B). These changes occurred without loss of cell
viability (Figure 1B). Pretreatment of cells with 3,6′-
dithiothalidomide prior to LPS (10 ng/ml) administration
reduced the synthesis of each factor in a dose-dependent
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manner (Figure 1C and D), likewise without loss of cell via-
bility (Figure 1D). The action of 3,6′-dithiothalidomide was
additionally assessed in an acute in vivo rodent LPS model.
Rats challenged with systemic LPS (i.p.) displayed a marked
time-dependent increase in plasma TNF-α protein that was
significantly attenuated by pretreatment with the agent
(Figure 1E). Notably within the CNS, hippocampal TNF-α
mRNA levels (Figure 1F) were elevated by LPS and mark-
edly suppressed by drug treatment, as were TNF-α protein
levels (Figure 1G).
3,6′-Dithiothalidomide treatment reduces LPS-induced
chronic neuroinflammation and restores LPS-mediated
abnormal hippocampal neuronal plasticity
The potential benefits of lowering TNF-α levels on
neuroinflammation-induced altered neuroplasticity were
assessed. To recreate the hostile brain microenvironment
associated with chronic neuroinflammation, we utilized the
properties associated with direct chronic CNS infusion of a
small quantity of LPS in rats. This infusion, with and with-
out systemic 3,6′-dithiothalidomide treatment, was well tol-
erated. When animals were allowed to explore an open
field arena for 10 min, no differences were observed in ei-
ther speed or exploration pattern (Figure 2A), indicating
that such treatments had no impact on levels of anxiety or
motility of animals. However, chronic i.c.v. LPS did induce
a significant increase in the number of granule cells expres-
sing the plasticity-related immediate early gene (IEG) Arc
within the suprapyramidal blade of the dentate gyrus
(Figures 2B and 3) compared to aCSF animals. No differ-
ences were observed within the infrapyramidal blade (not
shown). The IEG Arc is required for synaptic plasticity and
Figure 1 Pretreatment with 3,6′-dithiothalidomide significantly attenuates LPS-induced elevations in TNF-α in vitro and in vivo. (A)
Increasing concentration of LPS in RAW 264.7 cells induced a dose-dependent elevation in TNF-α and nitrite levels. (B) In the same cells, LPS
induced increases in media sAPP levels (n= 3); no cell toxicity was observed. (C) Pretreatment of cells with 3,6′-dithiothalidomide lowered the
levels of TNF-α and nitrite-induced by LPS (n= 3–4). (D) Likewise, in the absence of toxicity the drug reduced the levels of sAPP. (E) The effects of
intraperitoneal administration of LPS ± pretreatment with 3,6′-dithiothalidomide on rat plasma TNF-α levels over a 4-h time course are shown. LPS
induced a marked elevation of plasma TNF-α protein (n= 7–9), which was significantly reduced by drug (n= 4–5). (F) Compared to control (n= 6),
at 4 h, there was a marked LPS-induced increase in the levels of hippocampus TNF-α mRNA (n= 9). Pretreatment with drug significantly
attenuated the LPS-induced expression of TNF-α mRNA (n=5). (G) In line with LPS-induced systemic elevations in TNF-α, CNS TNF-α levels were
likewise significantly elevated. 3,6′-Dithiothalidomide fully ameliorated this increase and restored CNS TNF-α levels to baseline. Data are expressed
as mean± SEM of n observations; levels of statistical significance are indicated as follows: *P< 0.05, **P< 0.01, ***P< 0.001.
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is essential for memory processing [37,38]; behaviorally
induced Arc expression within the hippocampus is signifi-
cantly modified by chronic inflammation [39]. Notably, the
centrally mediated LPS-induced disturbances in Arc ex-
pression were abolished by systemically administered 3,6′-
dithiothalidomide. In parallel with Arc mRNA levels, the
number of OX-6 positive (MHC class II) microglial cells
was markedly elevated in LPS-treated animals, whereas
drug treatment prevented this rise (Figures 2C and 4). Fur-
thermore, GFAP immunofluorescence staining indicated a
marked upregulation in both the number and activated
Figure 2 Fourteen days after chronic intracerebroventricular
infusion of LPS in rats, an altered state of neuronal plasticity
and an elevated number of OX-6 positive microglial cells were
observed in the hippocampus. Co-administration of 3,6′-
dithiothalidomide suppressed these effects of LPS. (A) After
14 days co-administration of LPS (i.c.v. [40]) with 3,6′-
dithiothalidomide (i.p), no differences in the time spent in the outer
and inner zone of an exploration chamber were observed between
the treatment groups. In each animal cohort the rodents displayed a
preference for the outer zone rather than the inner zone. The mean
time spent in the two zones over the first 3 min of a 10-min
exploratory period is shown (aCSF + Veh n= 1; n= 4–9). (B) The
effects of the 10-min behavioral assessment on the immediate early
gene. Activity regulated cytoskeletal protein (Arc) gene expression in
the upper blade of the hippocampal neurons is presented; in situ
hybridization data indicate that there was an increase in the number
of neurons expressing Arc mRNA in LPS + vehicle-treated animals.
The behavior-LPS-induced elevation was prevented by treatment
with 3,6′-dithiothalidomide (n= 4–9). See Figure 3 for representative
images of Arc staining. (C) LPS administration induced a significant
increase in numbers of OX-6 positive microglial cells, while
treatment with 3,6′-dithiothalidomide prevented this effect of LPS.
See Figure 4 for representative images of activated microglia
staining. Data are expressed as mean ± SEM of n observations; levels
of statistical significance are indicated as follows: *P< 0.05.
Figure 3 3,6′-Dithiothalidomide (56 mg/kg i.p.) treatment
attenuates the aberrant expression of Arc mRNA induced by
intercerebroventricular administration of LPS after a uniform
level of behavioral activity. Representative flat images of neurons
labeled for Arc mRNA (red) within the DG, after behavioral
exploration of a novel environment for 10 min. Nuclei are
counterstained in green. The upper panel illustrates the numbers of
Arc positive (+ve) cells in animals infused with aCSF and treated
with drug vehicle. The middle panel displays the numbers of Arc +
ve cells in LPS-infused, vehicle-treated animals. The lower panel
shows the numbers of Arc + ve cells in LPS-infused, drug-treated
animals. The scale bar indicates 100 μm.
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morphology of astrocytes in response to LPS treatment;
these effects likewise were significantly attenuated by 3,6′-
dithiothalidomide (Figure 5).
3,6′-Dithiothalidomide treatment attenuates the effects of
central administration of toxic Aβ1–42 peptide on
behavior, cell viability and microglia activation
The direct administration of aged Aβ peptide, allowing
its oligomerization, into the CNS of wild-type (wt) mice,
was undertaken to emulate the inflammatory micro-
environment of the AD brain. In our study, a single i.c.v.
administration of Aβ1–42 was undertaken 7 days after
the initiation of a daily schedule of systemic (i.p.) 3,6′-
dithiothaliomide, utilizing a dose determined to be ef-
fective to ameliorate LPS-induced CNS elevations in
TNF-α in the prior studies. Control animals were
administered reverse peptide (with or without similar
3,6′-dithiothalidomide treatment). As illustrated in
Figures 6A and B, Aβ1–42 alone induced a marked deficit
in the learning ability of mice in the Morris Water Maze
paradigm (for both acquisition and retention). This was
accompanied by neuronal degeneration (assessed by
Fluoro-Jade B staining) and an increased presence of
CD11b-positive staining microglial cells within the den-
tate gyrus (DG) of the same animals (Figure 6C, D and
E). Treatment of mice with 3,6′-dithiothalidomide, prior
to Aβ1–42, markedly mitigated the actions of this toxic
peptide. Specifically, drug-treated animals performed at
a level similar to control mice in the Morris Water
Maze, and showed evidence of reduced levels of both
Figure 4 3,6′-Dithiothalidomide (56 mg/kg i.p.) treatment
suppresses the activation of microglial cells induced by the
intercerebroventricular administration of LPS. Representative flat
images of staining for activated microglial cells in the dentate gyrus
(DG) and CA3 areas of rat hippocampus are shown. The upper panel
illustrates high numbers of activated microglial cells after treatment
with LPS. The lower panel illustrates that drug treatment attenuates
the numbers of LPS-induced activated microglia. Microglia are
stained red; nuclei are counterstained green. The scale bar indicates
100 μm.
Figure 5 3,6′-Dithiothalidomide (56 mg/kg i.p.) treatment
reduces the activation of astrocyte cells induced by the
intercerebroventricular administration of LPS. Representative
images of GFAP + ve cells in a field of view of the granule cell layer
of the hippocampus are shown. The upper left panel (×20 objective
magnification for both treatments) illustrates the highly activated
numbers and morphology of astrocytes after the administration of
LPS; the smaller image is a higher magnification of a section from
the same image (×63 objective magnification, for both treatments).
The lower panel illustrates how drug treatment markedly reduces the
activated morphology of astrocytes after treatment with LPS;
similarly to the above, this effect is further illustrated in the higher
magnification side image. Astrocytes are stained red, whereas nuclei
are counterstained green.
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neuronal degeneration and CD11b positive microglial
cells in comparison to Aβ1–42 alone mice. No differences
were evident between mice administered Aβ42–1 with or
without drug treatment in any of the measured
parameters.
3,6′-Dithiothaliomide, administered daily for 6 weeks,
normalized age-associated biochemical, cellular and
behavioral features of AD observed in the 3xTg-AD
mouse model
Mice containing three transgenes (APPSwe + PS1M146V +
tauP301L) associated with AD [15] were utilized to assess
the effects of 3,6′-dithiothalidomide on two distinct age
groups of animals, of 10 and 17 months age at study
onset, referred to here as adult and old, respectively.
These two age ranges were selected based on prior stud-
ies [36,42] demonstrating that the line of 3xTg-AD mice
utilized in our study, which had been backcrossed onto a
C57BL/6 background for seven generations, presented
with brain AD pathology at 16 months age. Our chosen
age groups hence can be considered to be prior to and
post the onset of evident significant AD pathology, and
these 3xTg-AD mice were administered 3,6′-dithiothali-
domide or vehicle for 6 weeks thereafter.
Following the final assessment of mouse learning and
memory, animals were euthanized and various brain bio-
chemical measures were undertaken. As assessed in the
cerebral cortex, a trend to an elevated level in total APP
(6E10) was evident when comparing adult vehicle with
old vehicle animals (Figure 7A). 3,6′-Dithiothalidomide
Figure 6 3,6′-Dithiothalidomide (56 mg/kg i.p.) prevented Aβ1–42 peptide-induced memory defects, neuronal cell degeneration and
associated elevated CD11b staining of microglial cells. After 7 days of drug administration, aggregated Aβ1–42 peptide was administered
directly into the CNS (and reverse peptide Aβ42–1 was utilized as a control) (for aggregation/aging process, see [32,41]). Mouse memory function
was assessed by the Morris Water Maze; escape latencies measured over a 4-day trial period (A) and the final assessment undertaken 24 h after
the last training session are shown (B, n= 8). (C) After the completion of behavioral assessments mice were euthanized, and the levels of
neuronal degeneration were indicated by determining the level of Fluoro-Jade B labeling in the dentate gyrus; Aβ1–42 peptide induced a
significant degree of dye incorporation that was attenuated by 3,6′-dithiothalidomide (n= 3–4). (D) Numbers of CD11b-positive cells in the CA3
hippocampus region were determined to be elevated only in the vehicle + Aβ1–42 group (n= 3–4). (E) Representative photomicrographs of
Fluoro-Jade B-positive neurons in the dentate gyrus of control (vehicle-treated Aβ42–1-injected) mice, vehicle-treated Aβ1–42-injected mice and
3,6′-dithiothalidomide-treated Aβ1–42-injected mice. *Indicates comparisons with control (vehicle-treated Aβ42–1-injected) mice; #indicates
comparisons with 3,6′-dithiothalidomide-treated Aβ1–42-injected mice (n= 3–4). Data are expressed as mean ± SEM of n observations; levels of
statistical significance are indicated as follows: * or #P< 0.05, ** or ##P< 0.01, *** or ###P< 0.001.
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proved to be well tolerated by 3xTg-AD mice, and low-
ered total APP levels by 19% and 43% in adult and old
mice compared to their respective vehicle controls
(Figure 7A). Examination of soluble Aβ1–42 levels indi-
cated a marked age effect (Figure 7B), with old vehicle
controls expressing levels 143% of adult ones. This ele-
vation was fully inhibited by 3,6′-dithiothalidomide,
whose levels were similar to adult control and drug-
treated mice (Figure 7B). Total tau protein levels were
reduced (23%) in old vehicle animals compared to adult
ones, and were unaffected by drug treatment
(Figure 7C). However, levels of phosphorylated tau pro-
tein presented a strong age-associated rise (176% of
adult controls) that, similarly to soluble Aβ1–42 protein,
was attenuated by drug treatment in the older group
(Figure 7D). Interestingly, the levels of two synaptic mar-
kers, SNAP25 and synaptophysin, which showed a trend
to decline in the old vehicle control group (90% and 93%
of respective adult vehicle levels) were found to be sig-
nificantly elevated (19% and 37%, respectively) in old
drug-treated mice compared to old vehicle ones
(Figures 7E and F).
Immunohistochemical staining of insoluble Aβ plaques
indicated marked plaque formation only in the old
3xTg-AD mice; this Aβ plaque staining was dramatically
reduced by drug treatment (Figure 8A). Memory func-
tion, assessed by the Morris Water Maze, illustrated a
deficit in learning and acquisition of the location of the
Figure 7 3,6′-Dithiothalidomide (42 mg/kg i.p. once daily × 6 weeks) attenuated age-associated changes in hallmark features of AD in
old 3xTg-AD animals. Two cohorts of 3xTg-AD mice, adult and old, were evaluated after a 6-week regimen with daily administration of 3,6′-
dithiothalidomide or vehicle. After completion of the Morris Water Maze assessment animals were euthanized, and the levels of hallmark features
of Alzheimer’s disease were assessed. (A) Treatment with drug (n= 9) significantly reduced the levels of total APP in the old animals vs. old
control animals (n= 7). (B) Cortical soluble Aβ1–42 levels were increased in the old + control animals compared to younger adult + control (n= 7–
9, P< 0.01). Drug treatment reduced the soluble Aβ1–42 in the old mice (n= 8), but not in younger adult ones. (C) Levels of total tau protein were
lower in old control animals compared to younger adult control mice; however, drug treatment had no effect on total tau levels in either age
group. (D) Phosphorylated tau protein levels were elevated in old animals compared to younger adult animals (n= 8–9). Treatment of the old
animals with drug reduced levels of phosphorylated tau protein. The levels of SNAP 25 (E) and synaptophysin (F) were elevated in old drug-
treated mice (P< 0.01 and P< 0.05, both n= 7–9, respectively), compared to old vehicle animals. Data are presented in percent change from
appropriate control terms and are expressed as mean± SEM of n observations; levels of statistical significance are indicated as follows: *P< 0.05,
**P< 0.01, ***P< 0.001.
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hidden platform in old vehicle control mice during train-
ing (Figure 8B and C). Probe trial data obtained 4 h fol-
lowing their final training session indicated that these
old vehicle control animals failed to remember the loca-
tion of the platform, as illustrated by the low time spent
within the target zone as well as by the low number of
platform crossings (Figure 8C and D). 3,6′-
Dithiothalidomide abolished this age-associated memory
deficit (Figure 8B, C and D), with treated mice perform-
ing on par with adult vehicle control and drug-treated
animals.
The levels of CD68-positive microglial cells within the
subiculum and CA1 brain region were quantified as a
marker of the inflammatory microenvironment in the
Figure 8 3,6′-Dithiothalidomide (42 mg/kg i.p. once daily × 6 weeks) attenuated age-associated Aβ plaque deposition, memory deficits
and indices of neuroinflammation in the subiculum and CA1 region of the hippocampus in the elder of two cohorts of 3xTg-AD mice.
(A) Male 3xTg-AD mice displayed an age-dependent increase in Aβ plaque deposition; drug treatment reduced the numbers of Aβ plaques in
the older (old) animals. Upper panel: in younger adult (adult) animals (approximately 11.5 months of age at the time of death) few if any Aβ
plaques were detectable by immunohistochemical methods. However, in old animals (approximately 18.5 months of age at the time of death)
male 3xTg-AD mice presented marked deposition of Aβ plaques that were markedly reduced by drug treatment. Representative brain sections
illustrating the levels of Aβ plaque formation detected in the adult and old animals and the effects of 6 weeks of 3,6′-dithiothalidomide on
plaques are shown. (B) Morris Water Maze training over 6 days with four trials per day revealed a significant interaction between age and
treatment (F(1,33) = 4.77; P< 0.0360). In addition a main effect of treatment was observed F(1,33) = 5.34; P< 0.0272 (n= 7–9); specific comparisons
showed that drug treatment attenuated the learning deficits observed in the old group. (C and D) Probe trial performed 4 h after the last
training session on day 6 showed an interaction between age and drug treatment F(1,33) = 4.60; P< 0.0393. Treatment: F(1,33) = 4.26; P< 0.0468.
This indicated that drug-treated old mice were able to remember the location of the submerged platform more akin to that of the adult mice,
age and treatment for time in target zone: F(1,33) = 4.60; P< 0.0393; treatment: F(1,33) = 4.26; P< 0.0468. (E) The numbers of CD68 positive
microglial cells were significantly elevated in the old vehicle-treated mice compared to the drug-treated old and both sets of adult mice. Data are
expressed as mean± SEM of n observations; levels of statistical significance are indicated as follows: *P< 0.05, **P< 0.01, ***P< 0.001.
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hippocampus, as these regions are among those showing
the highest concentration of Aβ plaque staining
(Figure 8A). CD68-positive microglial cells were signifi-
cantly elevated in number (three-fold) only within old
vehicle control mice, and this rise was fully abolished by
the drug (Figure 8E). Hence, treatment with 3,6′-
dithiothalidomide induced a marked normalization of
key biochemical, learning and memory features of AD in
old 3xTg-AD mice.
Discussion
Here we demonstrate that the TNF-α-lowering agent,
3,6′-dithiothalidomide, ameliorates key aspects of neu-
roinflammation in multiple acute and longer term CNS
rodent models. Importantly, several of these models
emulate specific cardinal characteristics of AD, and high-
light the complex cyclic interaction among the synthesis
of TNF-α, the development of neuroinflammation and
impact on disease progression, inducing its advance-
ment. Our data suggest that breaking this cycle by low-
ering TNF-α generation and neuroinflammation can
favorably impact AD, as assessed at both a behavioral
and biochemical level, even late during the disease
course. Our studies hence reinforce the significant role
of neuroinflammation in AD and other degenerative
neurological disorders, and highlight the potential for
targeting TNF-α.
TNF-α has been implicated in the pathogenesis of a
wide number of neurological disorders, including AD,
PD, stroke and head trauma [5-12]. Indeed, TNF-α levels
have been found to be elevated within the CSF of AD
patients by as much as 25-fold [43], in line with substan-
tial elevations in TNF-α synthesis that were rapidly
induced in RAW 264.7 cells and animals challenged with
LPS (Figure 1A,E,F,G). Studies in subjects with mild cog-
nitive impairment (MCI) that progress to develop AD
suggest that increased CSF TNF-α levels are an early
event, and their rise correlates with disease progression
[44]. In accord with this, Janelsins and colleagues [23]
noted an elevated expression of TNF-α transcripts
within the entorhinal cortex of 3xTg-AD mice at
2 months, prior to the appearance of amyloid and tau
pathology, and this increase correlated with the onset of
cognitive deficits in these mice [45]. These studies, to-
gether with others demonstrating that (1) TNF-α poly-
morphisms that elevate TNF-α production may increase
AD risk, particularly in patients carrying one or more
apolipoprotein E E4 alleles [46-49], and that (2) genetic
ablation of TNF-α receptor 1 (TNFR1) in APP23 AD
mice [50] or a selective lowering of soluble TNF-α brain
levels in 3xTg-AD mice [25] reduces AD progression,
support the concept of TNF-α inhibition strategies for
treatment of AD [10,51,52].
Protein-based TNF-α inhibitors (etanercept and inflixi-
mab) that can effectively regulate circulating TNF-α
levels by binding them [53] have provided a means to
initially target brain TNF-α in AD, and perispinal etaner-
cept administration followed by Trendelenburg position-
ing in a small prospective open-label pilot study has
been reported to provide a rapid onset of cognitive im-
provement [54]. TNF-α levels can also be regulated at
the level of synthesis, which is tightly controlled at the
level of mRNA stability to facilitate rapid responses to
exogenous and endogenous stimuli [55], as occurs with
LPS and Aβ challenge, respectively, and hence is amen-
able to regulation by small-molecular-weight drugs. The
presence of adenylate-uridylate-rich elements (AREs)
within the 3′-UTR of TNF-α mRNA supports the poten-
tial for post-transcriptional repression, targeting it for
rapid degradation or inhibition of translation. This is
mediated through interactions with RNA-binding pro-
teins (RBPs), epitomized by HuR, which binds and stabi-
lizes ARE-containing transcripts and conveys them to
translational machinery to upregulate protein synthesis
and, conversely, by tristetraprolin, which aids the accel-
eration and degradation of bound mRNAs [56-59].
Exogenous signals, as arise from exposure to bacterial
proteins, potently induce inflammatory responses within
the CNS in a manner mimicked by RAW 264.7 cells
challenged with LPS [28]. The resulting elevation in
TNF-α derives from an LPS-mediated increase in the
half-life of TNF-α mRNA, allowing release of its transla-
tional repression. By contrast, translational blockade can
be induced by small-molecular-weight compounds, such
as thalidomide, which induce a shortening of the TNF-α
mRNA half-life [55]. In this regard, 3,6′-dithiothalido-
mide is a more potent TNF-α-lowering thalidomide
analogue that acts at the level of the 3′UTR of TNF-α
[27,60]. As is evident in Figure 1, LPS challenge to RAW
264.7 cells or animals activated toll-like receptors (TLR),
and induced the generation of TNF-α and nitrite, a
stable surrogate marker of highly unstable nitric oxide
production. APP levels also were elevated, in line with
prior studies [61] that additionally describe rises in inter-
leukin (IL)-1, 6 and 12, and cyclooxygenase-2 [62]. 3,6′-
Dithiothalidomide dose-dependently lowered LPS-
induced TNF-α, nitrite and APP levels in the absence of
cellular toxicity in RAW 264.7 cells, in contrast to thal-
idomide, which proved ineffective at concentrations up
to 30 μM (not shown), but has been reported to lower
APP levels in PC12 and SH-SY5Y neuronal cell lines
[63]. This action of 3,6′dithiothalidomide effectively
translated to both a systemic LPS challenge in vivo, low-
ering systemic and central TNF-α expression (Figure 1E-
G), as well as to a central LPS challenge.
Administered to brain, LPS reliably induces chronic
neuroinflammation associated with the activation of
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microglia, which is allied to impaired hippocampal-
dependent spatial cognitive function [17,18,21]. In the
present study this was achieved by the slow continuous
infusion of a low dose of LPS into the fourth ventricle of
the brain, which produced microglia activation within
the hippocampus and, importantly, induced abnormal
Arc expression in response to a simple behavioral task
(Figures 2 and 3). The activity-regulated, cytoskeleton-
associated IEG Arc is a key regulator of protein
synthesis-dependent forms of synaptic plasticity, which
are fundamental to memory formation [37,64,65]. In
healthy brain, Arc protein functions in a transient man-
ner, and its abnormally elevated sustained expression, as
occurs during neuroinflammation, may generate synaptic
noise and thereby impair long-term memory formation
[64]. Co-administration of systemic 3,6′-dithiothalido-
mide, which has been reported to readily enter the brain
(brain/plasma ratio 1.34) [30] and reversed an acute
LPS-mediated increase in TNF-α expression
(Figure 1G), fully inhibited LPS-induced activation of
microglia and the resulting altered coupling of neural ac-
tivity with de novo synthesis of Arc (Figures 4 and 3, re-
spectively). A similar dose of 3,6′-dithiothalidomide has
recently been described to normalize the expression of
Arc and to restore the acquisition and consolidation of
spatial memory impairments in a fully established model
of neuroinflammation [29], in which LPS was adminis-
tered to rodents for a full 28 days prior to drug treat-
ment (rather than in parallel with drug treatment, as in
the present study). In this study by Belarbi et al. [29],
3,6′-dithiothalidomide normalized LPS-induced eleva-
tions in brain TNF-α expression, but not IL-1β, and add-
itionally normalized the expression of specific genes
involved within the TLR-mediated signaling pathways
(in particular, TLR2, TLR4, Hmgb1 and IRAK1) that are
established to lead to elevated TNF-α expression [66].
Aβ, particularly in the form of soluble oligomeric as-
semblies or Aβ-derived diffusible ligands (ADDLs) [67-
69], has been described to target synapses, induce neur-
onal dysfunction and impair cognition. Its administra-
tion into the lateral ventricle of mice has been widely
used to model neuroinflammation and induce these AD-
related impairments [32,70-72], which in the present
study resulted in the activation of microglia and neur-
onal degeneration within the DG, accompanied by a
learning impairment in the Morris Water Maze para-
digm (Figure 6). Pretreatment of animals with 3,6′-
dithiothalidomide markedly inhibited each of these
aspects and, together with our prior studies, suggested
that the agent could prove of value in Tg models of AD
that, like the human condition, increasingly develop neu-
roinflammation during disease progression [23,24]. This
hypothesis was tested in two cohorts of 3xTg-AD mice
of 10 and 17 months age, chosen to represent times that
in our specific line coincided with the pre- and post-
development of amyloid plaques and neurofibrillary tan-
gles, as the presence of activated microglia in close prox-
imity to amyloid plaques is a cardinal feature of AD-
afflicted brain [73].
The pre-pathological upregulation of TNF-α and asso-
ciated enhancement of activated microglia have been
reported in the 3xTg-AD mouse model [23,25], and it
has been postulated that these activated immune cells
are key in the process of clearing extracellular Aβ [62].
A potential consequence of heightened Aβ exposure,
however, is microglia TLR4 stimulation and a resultant
upregulation of cytokine production and release [74].
TNF-α as well as IL-1β can correspondingly elevate Aβ
generation by stimulating γ-secretase activity [24,75], po-
tentially spawning a self-propagating positive feedback
loop of Aβ induction of inflammation and TNF-α signal-
ing that, in turn, may provoke further Aβ generation
[5,6,9,10,62]. In our study, in accord with the literature
[24], activated microglia were markedly elevated in old
versus adult vehicle-treated 3xTg-AD mice (Figure 8E),
which additionally presented with a significant elevation
in brain Aβ1–42 and phosphorylated tau levels, a decline
in total tau and a trend towards elevation of APP levels
(Figure 7). A substantial accumulation of extracellular
amyloid plaques was clearly evident within the cerebral
cortex and hippocampus of old versus adult 3xTg-AD
mice, which was accompanied by deficits in learning and
memory, as assessed within the Morris Water Maze
paradigm (Figure 8). The administration of 3,6′-
dithiothalidomide to old 3xTg-AD mice reversed each of
these parameters, significantly reducing Aβ1–42, phos-
phorylated tau and APP levels, lowering levels of acti-
vated microglia and fully ameliorating memory deficits
(Figures 7 and 8), which were accompanied by an eleva-
tion in synaptic protein markers (Figures 7E and F).
These drug-induced changes are in line with studies by
McAlpine and colleagues [25], demonstrating that block-
ade of TNF-α signaling (either by viral vector-mediated
expression of TNFR constructs or by crossing 3xTg-AD
mice with TNFR1 knockout mice) significantly sup-
pressed AD pathology. Importantly, our studies add-
itionally demonstrate that cognitive deficits that
accompany the classical pathology of AD appear to be
reversible, at least in the 3xTg-AD mouse model.
A caveat with this 3xTg-AD mouse model, like all such
models, is that it provides a partial model of the human dis-
ease. APP and tau expressions (specifically, human APPSwe
and human tauP301L) are driven in the 3xTg-AD model by
the unnatural mouse Thy1.2 regulatory element [22].
Hence, the possibility that some actions of 3,6′-dithiothali-
domide may be mediated via suppression of this unnatural
transgene promoter cannot be ruled out. Importantly, how-
ever, the action of 3,6′-dithiothalidomide to favorably lower
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APP levels as well as neuroinflammation in cellular studies
(Figure 1) occurred in cells controlled by their natural en-
dogenous regulatory elements, and wt rodents were used in
all other studies.
TNF-α has been shown to regulate numerous cellular
processes, not only inflammation and cell death, but also
cellular differentiation and survival, and achieves this by
binding and activating two cognate receptors, TNFR1
(p55) and TNFR2 (p75) [76]. TNFR1, expressed ubiqui-
tously including on neurons, astrocytes and microglia,
possesses an intracellular death domain and contributes
to neuronal dysfunction and death following activation
by soluble TNF-α [77], whereas TNFR2, principally
expressed on cells of hematopoietic origin but also on
neurons, has been associated with cell survival [76,78-
80] and chiefly responds to membrane-bound TNF-α
[81,82]. The engagement of homotrimeric TNF-α to ei-
ther receptor can activate three major signaling path-
ways: an apoptotic cascade initiated via the TNF-α
receptor-associated death domain, a nuclear factor kappa
B (NFκB) signaling pro-survival pathway implemented
via NFκB-mediated gene transcriptional actions, and a
JNK (c-Jun N-terminal kinase) cascade involved in cellu-
lar differentiation and proliferation that is generally pro-
apoptotic [62]. In large part, although the contrasting
pro-survival versus death-inducing actions of TNF-α
plausibly rely on the TNF-α receptor subtype activation,
the target cell types involved and their expression ratio
of TNFR1/2 and associated coupling proteins, the tem-
poral levels of available soluble and membrane-bound
TNF-α [79], and the scale and duration of neuroinflam-
mation combine in determining the eventual physio-
logical consequences of TNF-α receptor activation
[5,6,9,10,62]. Consequent to the diverse actions of TNF-
α and the influence of the brain microenvironment in
which they occur, it is hence not always clear under
which conditions TNF-α promotes beneficial versus
deleterious neuronal actions, and this, in large part,
accounts for how an initially pro-survival response may
develop into a pro-apoptotic one.
Under appropriate conditions TNF-α signaling, pri-
marily via TNFR2, can mediate homeostatic actions, epi-
tomized by its role in AMPA receptor surface expression
and synaptic scaling to impact LTP [83], as well as neu-
roprotective ones [9,10]. The genetic ablation of TNFR1
and -R2 in 3xTg-AD mice has been described to increase
the progression of AD pathology [84]. Furthermore,
TNF-α has a reported role in hippocampal development
and function [85] and, with the expression of both
TNFR1 and -R2 on neuronal progenitor cells, it can
modulate neurogenesis within the hippocampal neurons
under pathological conditions [86-89]. The finding that
adult 3xTg-AD mice were not detrimentally impacted by
3,6′-dithiothalidomide suggests that such homeostatic
actions of TNF-α signaling were largely unimpaired, al-
though clearly substantial classical preclinical toxico-
logical studies are warranted before the agent can be
considered for clinical use.
Conclusion
In synopsis, the present data demonstrate the key role of
TNF-α in acute and chronic neuroinflammatory models
that have relevance to neurodegeneration and, in par-
ticular, to AD and its progression. The TNF-α synthesis
inhibitor 3,6′-dithiothalidomide, administered at doses
that compare favorably to those of thalidomide in
human studies (100 to 1,200 mg daily [90]), appears to
advantageously reset the delicate balance between the
pro- versus anti-apoptotic actions of this signaling cas-
cade in the brain. This resulted in an inhibition of neu-
roinflammation and reduced AD progression in 3xTg-
AD mice, and thereby supports the feasibility of target-
ing TNF-α as a potential treatment strategy for AD and
other neurological disorders involving a neuroinflamma-
tory component.
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